share_log

三葉草生物-B：自願公告 三葉草生物公佈其二價RSV候選疫苗SCB-1019與GSK RSV疫苗AREXVY頭對頭比較獲得積極臨床數據

CLOVER BIO-B: VOLUNTARY ANNOUNCEMENT CLOVER ANNOUNCES POSITIVE CLINICAL DATA FOR RSV VACCINE CANDIDATE SCB-1019 COMPARED HEAD-TO-HEAD VERSUS GSK'S AREXVY

HKEX ·  Oct 29 06:10

Summary by Moomoo AI

三葉草生物-B（股份代號：2197）於2024年10月29日宣佈其二價RSV候選疫苗SCB-1019在Ⅰ期臨床試驗中與GSK的RSV疫苗AREXVY進行頭對頭比較，獲得積極的免疫原性和安全性數據。試驗結果顯示，SCB-1019在老年人受試者中誘導的RSV-A和RSV-B中和抗體的幾何平均滴度與AREXVY相當，且未使用佐劑的SCB-1019的局部不良事件發生率顯著低於使用AS01佐劑的AREXVY。此外，SCB-1019對RSV-B特異性抗體的反應趨勢高出約1.5倍。基於這些積極結果，三葉草生物計劃於2025年啟動進一步的臨床試驗，評估SCB-1019在RSV疫苗重複接種及呼吸道聯合疫苗的應用。公司股東及潛在投資者應審慎行事。
三葉草生物-B（股份代號：2197）於2024年10月29日宣佈其二價RSV候選疫苗SCB-1019在Ⅰ期臨床試驗中與GSK的RSV疫苗AREXVY進行頭對頭比較，獲得積極的免疫原性和安全性數據。試驗結果顯示，SCB-1019在老年人受試者中誘導的RSV-A和RSV-B中和抗體的幾何平均滴度與AREXVY相當，且未使用佐劑的SCB-1019的局部不良事件發生率顯著低於使用AS01佐劑的AREXVY。此外，SCB-1019對RSV-B特異性抗體的反應趨勢高出約1.5倍。基於這些積極結果，三葉草生物計劃於2025年啟動進一步的臨床試驗，評估SCB-1019在RSV疫苗重複接種及呼吸道聯合疫苗的應用。公司股東及潛在投資者應審慎行事。
Clover Biopharmaceuticals-B (stock code: 2197) announced on October 29, 2024 that its bivalent RSV candidate vaccine SCB-1019 achieved positive immunogenicity and safety data in Phase I clinical trials compared head-to-head with GSK's RSV vaccine AREXVY. The trial results showed that the geometric mean titers of neutralizing antibodies against RSV-A and RSV-B induced in elderly subjects by SCB-1019 were comparable to AREXVY, and the incidence of local adverse events of SCB-1019 without adjuvant was significantly lower than AREXVY with adjuvant AS01. In addition, the response trend of SCB-1019 to RSV-B specific antibodies was about 1.5 times higher. Based on these positive results, Clover Biopharmaceuticals plans to initiate further clinical trials in 2025 to evaluate the repeated administration of SCB-1019 in RSV vaccines and its application in respiratory co-administered vaccines. Shareholders and potential investors should proceed with caution.
Clover Biopharmaceuticals-B (stock code: 2197) announced on October 29, 2024 that its bivalent RSV candidate vaccine SCB-1019 achieved positive immunogenicity and safety data in Phase I clinical trials compared head-to-head with GSK's RSV vaccine AREXVY. The trial results showed that the geometric mean titers of neutralizing antibodies against RSV-A and RSV-B induced in elderly subjects by SCB-1019 were comparable to AREXVY, and the incidence of local adverse events of SCB-1019 without adjuvant was significantly lower than AREXVY with adjuvant AS01. In addition, the response trend of SCB-1019 to RSV-B specific antibodies was about 1.5 times higher. Based on these positive results, Clover Biopharmaceuticals plans to initiate further clinical trials in 2025 to evaluate the repeated administration of SCB-1019 in RSV vaccines and its application in respiratory co-administered vaccines. Shareholders and potential investors should proceed with caution.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated